Clincal observation of vidextus for HER-2 expressing locally advanced or metastatic solid tumors
Objective To explore the efficacy and safety of vidextus in patients with locally advanced or metastatic solid tumours expressing human epidermal growth factor receptor 2(HER-2).Methods From October 2021 to November 2023,43 patients with advanced solid tumours treated with vidextus were retrospectively reviewed.All patients had HER-2 immunohistochemical expression of at least+,and all the patients received vidextus monotherapy or combination therapy until intolerable adverse effects or disease progression occurred.Patients were evaluated for responce rate(RR),disease control rate(DCR),progression-free survival(PFS)and safety.Results In the 43 patients receiving vidextus,there were 17 cases(39.5%)of partial remission(PR),15 cases(34.9%)of stable disease(SD)and 11 cases(25.6%)of progressive disease(PD).The RR was 39.5%,and the DCR was 74.4%.In the HER-2 IHC(+/++)subgroup,the RR was 36.4%.In the HER-2 IHC(+++)subgroup,the RR was 42.9%.The median PFS was 4.4 months,the difference of median PFS in patients with different HER-2 expression or treatment was not significant(P>0.05).Safety analysis showed that myelosuppression was the most common adverse effect,and the most common grade 3 adverse effect was anaemia and neutropenia.No grade 4 adverse effect or death occured.Conclusion Vidextus showed good efficacy and a manageable safety profile in patients with locally advanced or metastatic solid tumours expressing HER-2.
NETL
NSTL
万方数据
